Ticker Hub
FATE — AI Analysis & Sentiment
3 recent AI-generated analyses for FATE. Sentiment and confidence insights updated continuously.
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
Positive early clinical data for FT836 de-risks the program and enhances future valuation for Fate Therapeutics, despite ongoing high cash burn.
Jun 1, 2026Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
Fate Therapeutics reported encouraging Phase 1 clinical results for its lupus drug candidate, which could boost its long-term pipeline value. The m...
Apr 30, 2026Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting
Fate Therapeutics' upcoming presentation of FT839 preclinical data at AACR is a positive catalyst for pipeline development. The market has not yet ...
Apr 16, 2026